Idean Marvasty

Idean M. serves as the Chief Financial Officer at Micron Biomedical, Inc. since 2021, where leadership has successfully secured $40 million in Series A financing aimed at enhancing global access to self-administered therapeutics and vaccines. Idean co-founded Antios Therapeutics in 2017 and led finance and strategy efforts, raising $201 million for hepatitis B cure development. Additionally, Idean co-founded G3 Therapeutics and the Global Institute for Research, focusing on finance and corporate affairs, raising $50 million for diagnostics and therapeutics projects and $2 million to develop a boutique CRO, respectively. Prior experience includes an advisory role at KPMG from 2010 to 2012, where guidance was provided to publicly traded and venture-backed firms on various strategic initiatives and compliance matters. Education was completed at the Georgia Institute of Technology.